Recent studies – in addition to new medication options that include CBD – have also shown promising results in various forms of epilepsy, including Dravet Syndrome. In summary findings published by the U.S. National Library of medicine, multiple small clinical trials have shown that CBD is able to reduce the number of seizures and severity of seizures for those that experience specific forms of epilepsy on a regular basis. (9)
There are more than 80 cannabinoids found in cannabis plants, with THC being the primary one, followed by CBD. However, in the hemp plant, which is a different strain of the species Cannabis sativa, CBD is the main active ingredient, and THC is barely present, making its use and legality more widespread. The reason that CBD is such an effective form of support for human health is due to the body’s endogenous cannabinoid system. This regulatory structure of the body has millions of cannabinoid receptors in the brain and nervous system, which react not only to plant-derived cannabinoids (such as hemp and marijuana) but also to natural cannabinoids produced within our body. When hemp oil is used and processed by the body, it is effectively boosting the function of the endocannabinoid system, helping our body regulate itself in many different ways.
As revealed by the results of a study published by the Addiction Journal and performed by University College London, smokers wishing to quit and treated with one 800mg dose of CBD, saw 40 percent more success in the first week of their attempt when using CBD products, than those treated with a placebo. Those treated with even a low dose of CBD claimed fewer intrusive thoughts, enabling them to go about their daily lives without the need for a cigarette, unlike those who were not given the cannabinoid. (6)
A survey of patients seen in a tertiary epilepsy center found that 21% of patients admitted to using marijuana in the last year, and 24% of patients believed marijuana to be effective for their seizures (10). While interesting, this anecdotal observation does not rise to the level of evidence needed to evaluate a potential new therapeutic modality.